Opinion: Philanthropic endowments at universities can offer a way out of biotech’s Valley of Death
With pharmaceutical companies being more risk-averse, academic drug discovery has the opportunity to focus on novel pathways and targets.
So many promising medical innovations never reach their full potential as therapies or cures, languishing instead in a metaphoric place many of us in biotech know as “the Valley of Death.”
This valley represents the gap between when a scientist makes a discovery and when that work has reached the point when a pharmaceutical company will license it, or a venture capital firm will invest in it, to get it to the point to help the patients who need it.
What's Your Reaction?
